Ibudilast

CHEMBL19449 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

230.3 g/mol

LogP

3.0

Phase

4

An anti-inflammatory drug studied for multiple sclerosis and migraine, inhibiting phosphodiesterase enzymes.

Berat Molekul

230,3100 g/mol

LogP

3,00

TPSA

34,40 Å²

Lipinski RO5

Lulus

Area Terapeutik

Migraine Multiple Sclerosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)C(=O)c1c(C(C)C)nn2ccccc12

InChI

InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3

Molecular Formula

C14H18N2O

HBD / HBA

- / 2

Ikatan yang Dapat Dirotasi

3

Atom Berat

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An anti-inflammatory drug studied for multiple sclerosis and migraine, inhibiting phosphodiesterase enzymes.

Yes, Ibudilast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL19449. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3671. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Ibudilast di PillFYI

Struktur

Data Cepat

Rumus: C14H18N2O

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.